Radiotherapeutic molecular medicine developer Molecular Insight Pharmaceuticals has named Donald Wallroth as its chief financial officer (CFO). Wallroth joins the Cambridge, Mass.-based Molecular Insight from the national life sciences practice of Tatum, an executive financial services firm.

Prior to joining Tatum, Wallroth held executive financial management positions with Keen Partners, GoldK, Transition Systems, Project Software and Development, Accenture, and Arthur D. Little, according to Molecular Insight.